Shares of SQZ Biotechnologies (NYSE:SQZ) have been assigned an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $38.33.
A number of brokerages have issued reports on SQZ. Brookline Capital Management restated a “buy” rating on shares of SQZ Biotechnologies in a research report on Tuesday, March 30th. Zacks Investment Research downgraded SQZ Biotechnologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 24th. Finally, Evercore ISI began coverage on SQZ Biotechnologies in a research report on Thursday, January 7th. They set an “outperform” rating on the stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of SQZ Biotechnologies in the fourth quarter worth approximately $352,000. Nuveen Asset Management LLC purchased a new stake in shares of SQZ Biotechnologies in the fourth quarter worth approximately $212,000. ETF Managers Group LLC purchased a new stake in shares of SQZ Biotechnologies in the fourth quarter worth approximately $350,000. Temasek Holdings Private Ltd purchased a new stake in shares of SQZ Biotechnologies in the fourth quarter worth approximately $72,854,000. Finally, Charles Schwab Investment Management Inc. bought a new position in SQZ Biotechnologies in the fourth quarter worth approximately $725,000.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
Read More: What is an inverted yield curve?
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.